Renaissance Technologies LLC decreased its position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) by 52.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 125,700 shares of the company’s stock after selling 141,107 shares during the quarter. Renaissance Technologies LLC’s holdings in Protara Therapeutics were worth $655,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in TARA. Rhumbline Advisers grew its holdings in Protara Therapeutics by 8.2% during the 3rd quarter. Rhumbline Advisers now owns 34,137 shares of the company’s stock worth $148,000 after acquiring an additional 2,596 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Protara Therapeutics by 26.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,736 shares of the company’s stock worth $111,000 after purchasing an additional 4,383 shares during the period. Two Sigma Investments LP lifted its position in shares of Protara Therapeutics by 35.8% in the 3rd quarter. Two Sigma Investments LP now owns 19,558 shares of the company’s stock worth $85,000 after purchasing an additional 5,154 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Protara Therapeutics by 7.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 102,499 shares of the company’s stock valued at $546,000 after purchasing an additional 6,725 shares in the last quarter. Finally, Quadrature Capital Ltd boosted its stake in shares of Protara Therapeutics by 39.4% during the fourth quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock valued at $129,000 after purchasing an additional 6,838 shares in the last quarter. 38.13% of the stock is currently owned by institutional investors.
Protara Therapeutics Price Performance
NASDAQ TARA opened at $3.97 on Monday. Protara Therapeutics, Inc. has a 52 week low of $2.97 and a 52 week high of $7.82. The company has a 50 day moving average price of $4.02 and a 200 day moving average price of $5.01. The firm has a market cap of $234.63 million, a PE ratio of -2.94 and a beta of 1.50.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on TARA. HC Wainwright reissued a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. UBS Group reaffirmed a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Oppenheimer lifted their price target on Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. Wall Street Zen lowered Protara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $26.25.
Get Our Latest Analysis on TARA
Protara Therapeutics Company Profile
Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.
Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.
See Also
- Five stocks we like better than Protara Therapeutics
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Want to see what other hedge funds are holding TARA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report).
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
